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ABSTRACT 
This open study was undertaken to assess the efficacy of clozapine in resistant schizophrenics, 
its side effects and safety profile and the mean dose required. Sample consisted of 28 patients who 
had been previously treated with neuroleptics and ECTs. A special proforma was prepared for 
recording the psychopathology and side effect profile. The complete blood count, differential count 
and BPRS scores were recorded weekly for a period of 3 months. Within 1 month of treatment on 
a dose range of 100-200 mg/day a 25%-50% decline in the BPRS score was noticed, the mean 
dose required was 241 mg/day. Sedation and sialorrhoea constituted the commonest side effects in 
90% patients. No case of agranulocytosis was reported. The implications of the study are discussed. 
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The introduction of typical neuroleptic 
agents in 1950 was a dramatic advance to treat 
patients with schizophrenia. Despite this a 
deterioration in the level of functioning and 
associated side-effects of neuroleptics still 
continue to be a problem in many 
schizophrenics. A relapse rate of 15-20% also 
occurs every year (Kane et al.,1988). Clozapine 
has been recommended in patients who are 
resistant to or intolerant of typical neuroleptics. 
According to Kane (1992) and Meltzer (1992), 
failure to respond to atleast two and/or three 
typical neuroleptics given for atleast 6 weeks 
each, should be considered as treatment 
resistant schizophrenia. 
The most exciting current development 
is the re-emergence of clozapine as a highly 
effective atypical antipsychotic drug for the 
treatment of resistant schizophrenics. Clozapine 
is a dibenzodiazepine with pharmacological and 
therapeutic profile that distinguishes it from 
classical antipsychotics like phenothiazines, 
butyrophenones, diphenyl butylpiperidines and 
schizophrenia 
thioxanthines. In contrast to these later groups, 
clozapine by virtue of its chemical structure 
exerts a weak antagonism at central dopami.ie 
D2 receptors and more pronounced inhibition of 
dopamine D, mediated activation of adenylate 
cyclase and potent blockade of central 
serotonergic, adrenergic and cholinergic 
receptors (Kaplan & Saddock,1996). More over, 
clozapine is only marginally effective in several 
animal behavioural models (e.g. induction of 
catalepsy and suppression of dopamine induced 
stereotypy). 
Early enthusiasm about the drug was 
marred by recognition in 1970, that it caused 
agranulocytosis. Only recently a sufficiently 
compelling data has been gathered that 
clozapine can be used safely if special 
surveillance is undertaken to monitor its 
potentially severe toxic effects (Anderman & 
Griffith, 1997). In our search for better treatment 
options for resistant schizophrenia, clozapine has 
definitely provided a ray of hope. The present 
study was undertaken to study the (1) efficacy 
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of clozapine (2) side effects and safety profile of 
clozapine and (3) mean effective dose required 
for the Indian setting. 
MATERIAL AND METHOD 
In an open and non-comparative study, 
the sample consisted of randomly selected 28 
patients who were attending the outpatients 
department of psychiatry, of a general municipal 
hospital. All the patients satisfied the DSM-IV 
criteria for schizophrenia (APA.1994). They were 
either chronic or acutely relapsed schizophrenics 
or those who were prone for the extra pyramidal 
side effects of potent neuroleptics. These 
patients were previously treated for a minimum 
of eight weeks with at least two neuroleptics viz, 
chlorpromazine (1000 mg/day or more), 
haloperidol or trifluoperazine in dose equivalents 
of 1000 mg/day of chlorpromazine and a course 
of 6-10 ECTs. None of the patients were on long 
term depot preparations. 
As they were found to be treatment 
resistant, they weretaken up for the study. Patients 
having comorbidity of affective disorders, 
substance use disorders or organic dysfunction 
were excluded from the study. After taking 
informed consent, the history was recorded as per 
the specially prepared proforma. Baseline 
investigations viz. complete haemogram, chest 
X-ray, SGOT, SGPT, ECG, serum creatinine and 
urine analysis were done before starting clozapine. 
The psychopathology, side-effect profile with the 
blood cell counts (TLC & DLC) and the dose of 
clozapine were recorded weekly. Brief Psychiatric 
Rating Scale (BPRS, Overall & Gorham,1962) 
was used to rate the psychopathology weekly. 
All the patients in this study were followed 
over a minimum period of three months to 
evaluate their improvement. Before the initiation 
of clozapine therapy a wash out period of 7 days 
was given to those patients who were on oral 
neuroleptics. Patients who were on a drug 
holiday or had relapsed after stopping 
neuroleptics were started on clozapine after 
doing the baseline investigations. The initial dose 
of clozapine was 25 mg/day which was increased 
to 100 mg/day by the end of two weeks. Then 
the doses were titrated accordingly with 
increments being made by 25-50 mg every week. 
The gradual titration was done to see the 
therapeutic response to the minimum dose of 
clozapine and/or »he presence of side effects with 
the maximum dose range being 425-525 mg/ 
day by the end of three months. The side effects 
were recorded weekly and the scores were 
calculated at the end of 3 months as the total 
percentage of patients exhibiting them. A watch 
was kept for a decrease in the leucocyte count 
below 3000/cu mm or in the granulocyte count 
below 1500/cu mm which would necessitate 
discontinuation of clozapine. The total BPRS 
scores were compared at the end of 1 and 3 
months respectively from the baseline score with 
the help of the paired t-test and the percentage 
improvement in the BPRS score at the end of 
three months was noted. 
RESULTS 
The population under study consisted of 
28 patients, with age ranging from 15 to 60 years 
and a mean age of 32.64±13.73 years. There 
were 13 males (46.43) and 15 females (53.57%). 
Most of the patients were from low or lower 
middle socio-economic class with poor 
educational background. 
TABLE 1 
BPRS TOTAL SCORES 
MEAN S.D. 
Baseline 29.75 9.49 
After 1 month 19.70 8.10* 
After 3 months 14.71 7.08 ** 
* Paired T value =4.34; d.f.=27; (p<0.005) 
** Paired 'f value = 8.89 ; d.f.=27; (p<0.005) 
The BPRS scores when compared from 
baseline (29.75±9.49) showed improvement both 
at the e> d of one month (19.7±8.1) and three 
months J4.71±7.08), which was statistically 
significant. 
When the percentage improvement in the 
BPRS scores at the end of 3 months was 
assessed, it was found that of 28 patients, 14 
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TABLE 2 
PERCENTAGE IMPROVEMENT ON BPRS 
TOTAL SCORES FROM BASELINE 
Percentage Improvement After 3 months (N=28) 
0-25 3(10.71%) 
26-50 14(50.00%) 
51-75 10(35.72%) 
76 & above 1( 3.57%) 
(50%) had shown improvement in the range 
26-50%, with 10(35.72%) patients having 
improvement in the range of 51-75% whereas 
only 3(10.71%) patients did not show 
improvement beyond 25% from the baseline. 
TABLE 3 
SIDE EFFECT PROFILE OF CLOZAPINE 
OVER 3 MONTHS 
Symptoms 
Sedation 
Sialorrhoea 
Dizziness 
Constipation 
Hypotension 
Weight gain 
Tachycardia 
G.I. Upset 
Total No. of Patients (n=28) 
26 
26 
16 
14 
11 
11 
5 
4 
Anticholinergic effects 2 
Fainting Spells 
Myoclonus 
Seizures 
Agranulocytosis 
2 
(92.85%) 
(92.85%) 
(57.14%) 
(50.00%) 
(42.85%) 
(42.85%) 
(17.85%) 
(14.28%) 
( 7.14%) 
( 7.14%) 
— 
_. 
— 
The side effects profile revealed sedation 
and sialorrhoea to be the most frequently 
observed side effects in 26(92.85%) patients. 
Hypotension and weight gain were seen in 11 
(42.85%) patients. 
A significant finding was that none of the 
patients developed agranulocytosis. The regular 
monitoring of the blood count towards the end 
of 3 months, revealed an increase in the count 
in 7(25%) patients, though it was not above 
13,000/cu mm and a decrease in 4(14.28%) 
patients but not below 4,000/cu mm. 
The mean dose of clozapine in our study 
was 241 mg/day. As evident from the table, only 
6(21.45%) patients required doses more than 
325 mg/day by the end of 3 months. 9(32.13%) 
patients were receiving clozapine in the range 
226-325 mg/day, 8 (28.57%) patients responded 
TABLE 4 
DOSE OF CLOZAPINE 
Dose Range 
(mg/day) 
25-125 
126-225 
226 - 325 
326 - 425 
426 - 525 
At 3 Months 
Total No. of Patients (n=28) 
5(17.85%) 
8(28.57%) 
9(32.13%) 
4(14.30%) 
2( 7.15%) 
to clozapine in the range 126-225 mg/day 
whereas, 5(17.85%) patients were maintained 
on doses between 25-125 mg/day. 
DISCUSSION 
Clozapine has found to result in moderate 
to marked overall symptomatic improvement in 
approximately 60-80% of patients with acute or 
chronic schizophrenia. Marked improvement 
consistently occurred in symptoms of 
hallucinations, hostility and thought disorders 
(Klik,1976; Lapierre,1980). This finding was also 
seen in our study where many of the positive 
symptoms of schizophrenia responded earlier 
when rated on the BPRS. As we had not used 
the Positive and Negative Syndrome Scale (Kay 
et al.,1988), we could not comment on those 
patients having associated negative symptoms 
or their improvement in comparison to the 
positive symptoms in our study. 
Though clozapine is more propagated for 
the negative symptoms of schizophrenia, it 
definitely improves the positive symptoms much 
earlier in treatment resistant schizophrenics 
(Kane, 1988). Meltzer et al.(1989) reported that 
affective flattening and anhedonia did not respond 
to clozapine. Studies by Conley et al. (1994) and 
Brier et al.(1994) also suggest that the drug helps 
only in ameliorating the secondary negative 
symptoms rather than the primary negative 
symptoms. Kane (1993) also reported a pronounced 
anxiolytic effect within 1-2 weeks of clozapine 
therapy, before the onset of its antipsychotic action. 
A 50-75% decrease in the total BPRS 
score with clozapine was seen in 35.72% of our 
patients by the end of 3 months. However, 
previous studies revealed only a 20% CLOZAPINE IN TREATMENT OF RESISTANT SCHIZOPHRENIA 
improvement in 40-60% of patients over a period 
of 1.5 to 6 months (Lindstrom,1988; Meltzer et 
a!.1989; Mattes, 1989; Brier et al.,1993). These 
studies also reported that the benefits occurred 
in the early phase of treatment and stabilised in 
the initial 3-6 months after which, no further 
benefit was seen. It also remains to be seen 
whether the patients in our study would have 
shown further improvement or reached a plateau 
as the study was terminated at this point. 
Clozapine became unpopular due to its 
dangerous side effect of agranulocytosis, which is 
reversible in early stages with a maximum risk 
being in the first 18 weeks of treatment 
(Anderman,1977; Andrew & Rennie,1990). 
Fortunately, none of our patients developed this 
potentially dangerous side effect. Lieberman et 
al.(1988) cited a 2% cumulative incidence after 
52 weeks of clozapine treatment for 
agranulocytosis. However, benign leucocytosis can 
occur in the initial stages, which was also seen in 
our study (Kaplan et al.,1996). Sedation, 
sialorrhoea, dizziness and hypotension were the 
most commonly seen side effects in our patients, 
a fact which was also reported in previous studies 
(Fitton & Heel,1990; Brier et al.,1994). 42% of our 
patients complained of weight gain, keeping in with 
the study by Umbricht et al. (1994). Most of these 
low dose side effects are associated with clozapine 
titration and tend to lessen and disappear when 
dosage reaches 300-400 mg/day. However, we did 
not notice much diminution in the frequency of the 
observed side effects during our study period. 
The data on the dose range of clozapine 
revealed a lower mean dose of 241 mg/day, in 
the Indian population as per our study which was 
similar to the trial conducted in Europe where 
the mean dose was 283 mg/day. However, 
studies in the US revealed higher mean dose of 
444 mg/day though the response rate was 
strikingly similar (Fleischhacker,1994). This 
finding is significant because if patients can be 
maintained on a lower dose then the toxic side-
effects can be avoided. 
In conclusion, this trial was conducted to 
study the efficacy of clozapine in treatment 
resistant schizophrenics does propagate the 
benefits of the drug. It also reveals that there are 
no dangerous side effects of the drug except for 
sedation and sialorrhoea which may decrease with 
clozapine titration. The required mean dose in 
our study was much less than in the western 
counter parts. Though the study sample was small 
and screened over 3 months, a larger sample with 
an adequate time span would be more fruitful in 
yielding the shortcomings of the present study. 
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